The French Government Defence procurement agency invests €900,000 towards Pherecydes Pharma managed €1.2-million project, involving several university and military laboratories.
Pherecydes Pharma is attending the Forum coorganised by PHAG ESPOIRS and LE LIEN associations, as well as their partners, Narbonne Hospital and City, on January 25, 2012 in Narbonne - France, at 9h15, in Le Théatre.
Biotech Finance press details the purpose of this investiment targeting the set up of a phage bioproduction unit and testing of 2 therapeutic products in human clinical trials.
Meeting the Belgian biotech companies at the 2011 Forum Bio-Entrepreneurs held in the Bourse de Commerce de Paris, December 6, 2011.
Perspectives
Nanotechnology and nanodevices
With the full control of T4 phage replication cycle and the possibility to introduce mutations and/or coding sequences as needed, without affecting the main phage functions, Pherecydes Pharma owns a biodevice with applications in nanotechnologies.
We are open to discuss potential collaborations for developing under contract or co-developing new nanodevices with applications in various fields.
- Phage therapy biodrugs;
- Medical application diagnostic tools.